B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

References

• RahmanAIsenbergDASystemic lupus erythematosusN Engl J Med2008358992993918305268
   PubMed Web of Science ®Google Scholar
• TanEMCohenASFriesJFThe 1982 revised criteria for the classification of systemic lupus erythematosusArthritis Rheum19822511127112777138600
   PubMed Web of Science ®Google Scholar
• HochbergMCUpdating the American College of Rheumatology Criteria for the classification of systemic lupus erythematosusArthritis Rheum199740917259324032
   PubMed Web of Science ®Google Scholar
• UrowitzMBBookmanAAKoehlerBEGordonDASmytheHAOgryzloMAThe bimodal mortality pattern of systemic lupus erythematosusAm J Med19766022212251251849
   PubMed Web of Science ®Google Scholar
• Wiesik-SzewczykELackiJKFeleszkoWOlesinskaMTarget therapies in systemic lupus erythematosus: current state of the artMini Rev Med Chem92010101095696521034417
   PubMed Web of Science ®Google Scholar
• MerrillJEnding the 50-year drought of FDA drug approval for SLEBull NYU Hosp Jt Dis201169323824222035436
   PubMedGoogle Scholar
• LipskyPESystemic lupus erythematosus: an autoimmune disease of B cell hyperactivityNat Immunol20012976476611526379
   PubMed Web of Science ®Google Scholar
• AnolikJHB cell biology and dysfunction in SLEBull NYU Hosp Jt Dis200765318218617922667
   PubMedGoogle Scholar
• JacobiAMDiamondBBalancing diversity and tolerance: lessons from patients with systemic lupus erythematosusJ Exp Med2005202334134416061723
   PubMed Web of Science ®Google Scholar
• YurasovSWardemannHHammersenJDefective B cell tolerance checkpoints in systemic lupus erythematosusJ Exp Med2005201570371115738055
   PubMed Web of Science ®Google Scholar
• ArechigaAFHabibTHeYCutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signalingJ Immunol200918263343334719265110
   PubMed Web of Science ®Google Scholar
• HomGGrahamRRModrekBAssociation of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAXN Engl J Med2008358990090918204098
   PubMed Web of Science ®Google Scholar
• LiuZDavidsonABAFF and selection of autoreactive B cellsTrends Immunol201132838839421752714
   PubMed Web of Science ®Google Scholar
• NashiEWangYDiamondBThe role of B cells in lupus pathogenesisInt J Biochem Cell Biol201042454355019850148
   PubMed Web of Science ®Google Scholar
• SilvermanJGWiesmanSRituximab therapy and autoimmune disorders: prospects for anti-B cell therapyArthritis Rheum20034861484149212794814
   PubMed Web of Science ®Google Scholar
• AnolikJHBarnardJCappioneARitiximab improves peripheral B cell abnormalities in human systemic lupus erythematosusArthritis Rheum200450113580359015529346
   PubMed Web of Science ®Google Scholar
• VallerskogTGunnarssonIWidheMTreatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLEClin Immunol20071221627417046329
   PubMed Web of Science ®Google Scholar
• AnolikJHBarnardJOwenTDelayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapyArthritis Rheum20075693044305617763423
   PubMed Web of Science ®Google Scholar
• VitalEMDassSBuchMHB cell biomarkers of rituximab responses in systemic lupus erythematosusArthritis Rheum201163103038304721618204
   PubMed Web of Science ®Google Scholar
• MerrillJTNeuweltCMWallaceDJEfficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trialArthritis Rheum201062122223320039413
   PubMed Web of Science ®Google Scholar
• MerrillJBuyonJFurieRAssessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)Lupus201120770971621478286
   PubMed Web of Science ®Google Scholar
• NavarraSVGuzmanRMGallacherAEfor BLISS-52 Study GroupEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialLancet2011377976772173121296403
   PubMed Web of Science ®Google Scholar
• FurieRPetriMZamaniOfor BLISS-76 Study GroupA phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis Rheum201163123918393022127708
   PubMed Web of Science ®Google Scholar
• FurieRAPetriMAWallaceDJNovel evidence-based systemic lupus erythematosus responder indexArthritis Rheum20096191143115119714615
   PubMed Web of Science ®Google Scholar
• RovinBHFurieRLatinisKfor LUNAR Investigator GroupEfficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab studyArthritis Rheum20126441215122622231479
   PubMed Web of Science ®Google Scholar
• Galarza-MaldonadoCKourilovitchMRMolinerosJEThe administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosusAutoimmun Rev201010210811120804861
   PubMed Web of Science ®Google Scholar
• CatapanoFChaudhryANJonesRBSmithKGJayneDWLong-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosusNephrol Dial Transplant201025113586359220466686
   PubMed Web of Science ®Google Scholar
• LeandroMJCambridgeGEdwardsJCEhrensteinMRIsenbergDAB-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patientsRheumatology (Oxford)200544121542154516188950
   PubMed Web of Science ®Google Scholar
• LooneyRJAnolikJHCampbellDB cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximabArthritis Rheum20045082580258915334472
   PubMed Web of Science ®Google Scholar
• NgKPCambridgeGLeandroMJEdwardsJCEhrensteinMIsenbergDAB cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of responseAnn Rheum Dis20076691259126217412738
   PubMed Web of Science ®Google Scholar
• CambridgeGIsenbergDAEdwardsJCB cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical responseAnn Rheum Dis20086771011101617962238
   PubMed Web of Science ®Google Scholar
• AlbertDDunhamJKhanSVariability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosusAnn Rheum Dis200867121724173118250115
   PubMed Web of Science ®Google Scholar
• ReynoldsJAToescuVYeeCSPrabuASitunayakeDGordonCEffects of rituximab on resistant SLE disease including lung involvementLupus2009181677319074171
   PubMed Web of Science ®Google Scholar
• TanakaYYamamotoKTakeuchiTA multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosusMod Rheumatol200717319119717564773
   PubMedGoogle Scholar
• LuTYNgKPCambridgeGA retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patientsArthritis Rheum200961448248719333973
   PubMed Web of Science ®Google Scholar
• Garcia-CarrascoMMendoza-PintoCSandoval-CruzMAnti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patientsLupus201019221321919965944
   PubMed Web of Science ®Google Scholar
• TerrierBAmouraZRavaudPfor Club Rhumatismes et InflammationSafety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registryArthritis Rheum20106282458246620506527
   PubMed Web of Science ®Google Scholar
• JónsdóttirTGunnarssonIRisseladaAHenrikssonEWKlareskogLvan VollenhovenRFTreatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of responseAnn Rheum Dis200867333033417827182
   PubMed Web of Science ®Google Scholar
• Gomard-MennessonERuivardMKoenigMTreatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 casesLupus200615422323116686262
   PubMed Web of Science ®Google Scholar
• LindholmCBörjesson-AspKZendjanchiKSundqvistACTarkowskiABokarewaMLongterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosusJ Rheumatol200835582683318398943
   PubMed Web of Science ®Google Scholar
• Díaz-LagaresCCrocaSSangleSfor UK-BIOGEAS RegistryEfficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohortsAutoimmun Rev201211535736422032879
   PubMed Web of Science ®Google Scholar
• LateefALahiriMTengGGVasooSUse of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experienceLupus201019676577020118162
   PubMed Web of Science ®Google Scholar
• BoletisJNMarinakiSSkaliotiCLionakiSSIniotakiASfikakisPPRituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective studyNephrol Dial Transplant20092472157216019179411
   PubMed Web of Science ®Google Scholar
• JónsdóttirTSundelinBWelin HenrikssonEvan VollenhovenRFGunnarssonIRituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense depositsAnn Rheum Dis20117061172117321367763
   PubMed Web of Science ®Google Scholar
• MelanderCSalléeMTrollietPRituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcomeClin J Am Soc Nephrol20094357958719261822
   PubMed Web of Science ®Google Scholar
• JónsdóttirTGunnarssonIMourãoAFLuTYvan VollenhovenRFIsenbergDClinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohortsRheumatology (Oxford)20104981502150420427294
   PubMed Web of Science ®Google Scholar
• Ramos-CasalsMDiaz-LagaresCSoto-CardenasMJRituximab therapy in lupus nephritis: current clinical evidenceClin Rev Allergy Immunol201140315916920419398
   PubMed Web of Science ®Google Scholar
• PepperRGriffithMKirwanCRituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroidsNephrol Dial Transplant200924123717372319617257
   PubMed Web of Science ®Google Scholar
• TokunagaMSaitoKKawabataDEfficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous systemAnn Rheum Dis200766447047517107983
   PubMed Web of Science ®Google Scholar
• NarváezJRíos-RodriguezVde la FuenteDRituximab therapy in refractory neuropsychiatric lupus: current clinical evidenceSemin Arthritis Rheum201141336437221875742
   PubMed Web of Science ®Google Scholar
• ContiFPerriconeCCeccarelliFValesiniGRituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: Two sides of the same coinAutoimmun Rev201091171672020667484
   PubMed Web of Science ®Google Scholar
• BruceINGordonCMerrillJTIsenbergDClinical trials in lupus: what have we learned so far?Rheumatology (Oxford)20104961025102720123955
   PubMed Web of Science ®Google Scholar
• MerrillJTBuyonJPRituximab: wanted dead or aliveArthritis Rheum20106282188219120506315
   PubMed Web of Science ®Google Scholar